Fuisz Pharma Announces Patented Communication of Analyte Information Between Microchip Containing Smart Tablet and a Body Fluid Analyzer
MIAMI, Feb. 7, 2011 /PRNewswire/ — Based on U.S. Patent 7,824,612 (“Body Fluid Analyzer and System including Same and Method for Programming Same”), Fuisz Pharma today announced the use of their patented Technology to create a new class of microchip containing smart tablets that communicate with personal body fluid analyzers.
These tablets wirelessly inform a body fluid analyzer of acceptable analyte values for body fluids, set by the drug company so that the analyzer can provide alerts where the patient’s results exceed a threshold value.
Joseph Matus Fuisz, CEO of Fuisz Pharma, states, “We are seeing extraordinarily exciting developments around the use of microchip enabled smart tablets that can wirelessly communicate pertinent information to receiving devices. At the same time, we are seeing further growth in the capabilities of personal body fluid analyzers and a greater appreciation for their use in drug development and personalized medicine. Thus, we see the use of our patent 7,824,612 to enable the value added connection of tablet smart chips together with personal analyzers to convey a broad spectrum of pertinent information. This enhances the function of smart tablets and analyzers alike.”
About Fuisz Pharma:
Fuisz Pharma (www.fuisz.com) is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma.
SOURCE Fuisz Pharma